GCA
GILD icon

Genesee Capital Advisors’s Gilead Sciences GILD Stock Holding History

Genesee Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,738
Closed -$1.03M – 119
2023
Q3 		$1.03M Sell
13,738
-162
-1% -$12.5K 0.74% 36
2023
Q2 		$1.07M Buy
+13,900
New +$1.11M 0.73% 40

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Genesee Capital Advisors's GILD Position: Q4 2023 in Review

Genesee Capital Advisors sold out of Gilead Sciences (GILD) in Q4 2023, closing a stake of 13,738 shares — an estimated $1.03M sold.

Genesee Capital Advisors first reported a position in GILD in Q2 2023 and held it in 2 quarters. The position peaked at $1.07M in Q2 2023. 1,775 funds tracked by Wall St. Rank hold GILD as of Q4 2023.

  • Genesee Capital Advisors reported no remaining Gilead Sciences position as of Q4 2023 after selling out during the quarter.
  • Genesee Capital Advisors sold 13,738 Gilead Sciences shares in Q4 2023, an estimated $1.03M.
  • Genesee Capital Advisors first reported a position in Gilead Sciences in Q2 2023 and held it in 2 quarters.
  • Genesee Capital Advisors's Gilead Sciences position peaked at $1.07M in Q2 2023.
  • 1,775 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2023.

Based on Genesee Capital Advisors's 13F filing for Q4 2023, filed 29 Jan 2024.